PRTN3 and vasculitis: When the results of positive C-ANCA and anti-PR3 antibodies were available, a decision was taken to continue with the anti-thyroid medication based on the reasons that the patient has been C-ANCA positive prior to initiating therapy and there was no clinical evidence suggesting that the patient's chronic symptoms related to the vasculitis were worsening since receiving the medications.